FDA Approves First Biosimilar to Treat Macular Degeneration Disease and Other Eye Conditions
For Immediate Release: September 20, 2021 The U.S. Food and Drug Administration today approved Byooviz (ranibizumab-nuna) as the first biosimilar to Lucentis (ranibizumab injection) for the treatment of several eye diseases and conditions, including …